The trading price of Intra-Cellular Therapies Inc (NASDAQ:ITCI) floating higher at last check on current market day and closing at $86.71, 12.98% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it has been fluctuating between $76.76 and $87.7. In examining the 52-week price action we see that the stock hit a 52-week high of $84.89 and a 52-week low of $45.50. Over the past month, the stock has gained 19.35% in value.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Intra-Cellular Therapies Inc, whose market valuation is $9.16 billion at the time of this writing, is expected to release its quarterly earnings report on 2024-Oct-30. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -0.2 per share this quarter, however they have predicted annual earnings per share of -0.68 for current year and 0.76 for next year.
Analysts have forecast the company to bring in revenue of 172.35M for the current quarter, with the likely lows of 165M and highs of 175.27M. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue is 666.57M.
On the technical side, indicators suggest ITCI has a 100% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 100% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned ITCI a recommendation rating is 6. Out of them, 0 rate it a Hold, while 6 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Intra-Cellular Therapies Inc (ITCI) as Underweight, while 0 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that ITCI’s price is currently 14.56% off the SMA20 and 15.92% off the SMA50. The RSI metric on the 14-day chart is currently showing 76.12, and weekly volatility stands at 2.39%. When measured over the past 30 days, the indicator reaches 2.40%. Intra-Cellular Therapies Inc (NASDAQ:ITCI)’s beta value is currently sitting at 0.99, while the Average True Range indicator is currently displaying 2.52. With analysts defining $70-$107 as the low and high price targets, we arrive at a consensus price target of $100 for the trailing 12-month period. The current price is about 19.27% off the estimated low and -23.4% off the forecast high, based on this estimate. Investors will be thrilled if ITCI’s share price rises to $100, which is the median consensus price. At that level, ITCI’s share price would be -15.33% below current price.
To see how Intra-Cellular Therapies Inc stock has been performing today in comparison to its peers in the industry, here are the numbers: ITCI stock’s performance was 12.98% at last check in today’s session, and 87.00% in the past year.
An evaluation of the daily trading volume of Intra-Cellular Therapies Inc (NASDAQ:ITCI) indicates that the 3-month average is 520.62K. However, this figure has increased over the past 10 days to an average of 0.45.
Currently, records show that 105.67 million of the company’s shares remain outstanding. The insiders hold 6.53% of outstanding shares, whereas institutions hold 91.83%. The stats also highlight that short interest as of 2024-10-15, stood at 2.42 million shares, resulting in a short ratio of 5.1 at that time. From this, we can conclude that short interest is 262.00 of the company’s total outstanding shares. It is noteworthy that short shares in October were down slightly from the previous month’s figure, which was 2.57 million. However, since the stock’s price has seen 21.07% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
